Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

g research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses.  The Company's current programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are large markets not adequately served by current therapeutic options.  For more information, please visit the Neurologix website at http://www.neurologix.net/.

Cautionary Statement Regarding Forward-Looking Statements

This news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:


    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
    2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
    3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
    4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
    5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
    6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
    7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
    8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
    9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
    10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced completion of enrollment in its first ... the 3-month observations confirmed the 1-month findings that ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
    (Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
    (Date:12/15/2014)... 15, 2014 BerGenBio AS, a ... drug resistant cancers, today announces that it has raised ... from new and existing investors. BerGenBio will ... development of its pipeline of innovative cancer therapeutics, in ... drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, ...
    Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
    (Date:12/19/2014)... Norton HealthDay Reporter THURSDAY, ... who were exposed to high levels of air pollution late ... a U.S. study suggests. Researchers found that of nearly ... those exposed to the most air pollution during pregnancy were ... autism. And exposure during the third trimester, specifically, showed the ...
    (Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue eye ... significantly reduce the risk of vision loss in patients ... British researchers led by David Garway-Heath, of the Moorfields ... tracked outcomes for more than 500 people newly diagnosed ... the disease and one of the leading causes of ...
    (Date:12/17/2014)... Myo Nwe is the co-author of a new weight loss ... of the Ace Medical Weight Loss Center in Rock Hill, ... at the industry of weight loss, and how several fad ... in television shows, however, she says the topic of obesity ... for basic laughs, which she believes impacts whether Americans view ...
    (Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
    (Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
    Breaking Medicine News(10 mins):Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
    ... Jerry Posakony, scientist at the Department of Energy,s Pacific ... Association of Engineering Societies for his pioneering contributions to ... evaluation technologies. AAES has awarded the John Fritz ... engineer and 15th president of the American Society of ...
    ... finds 3 percent of those who get something lodged in ... Although the number of young children who choke after swallowing ... when that happens is real, the latest research indicates. , ... study author Dr. Rahul K. Shah, a pediatric otolaryngologist with ...
    ... researchers in the University of Alabama at Birmingham (UAB) ... identify potential dangers on playgrounds and in gymnasiums and ... The tools consist of two checklists that ... facilities and equipment on playgrounds and in gymnasiums. The ...
    ... The ... 146 medical schools and schools of osteopathic medicine nationwide, jumping from 32nd in 2005. ... New York (Vocus) April 19, 2010 -- ... 18th out of 146 medical schools and schools of osteopathic medicine nationwide, jumping from 32nd in ...
    ... ... leadership through technology innovation and improved usability. , ... (PRWEB) April 19, 2010 -- FileTrail, ... announced the release of FileTrail 4.0. This new release extends the company,s leadership ...
    ... ... the Easy Water system in Austin, Texas. The Easy Water system is a revolutionary alternative ... as calcium and magnesium in your water, without them resulting in hard water buildup. ... Austin, Texas -- 1st Plumbing ...
    Cached Medicine News:Health News:Fatal Choking a Real Risk Among Toddlers 2Health News:Fatal Choking a Real Risk Among Toddlers 3Health News:Free UAB service to help parents advocate for safer playgrounds, gyms 2Health News:Mount Sinai School of Medicine Ranked in the Top 20 Best Medical Schools by US News & World Report 2Health News:Newest Release of FileTrail Sets New Standard in Global Physical Records Management and File Tracking 2Health News:Newest Release of FileTrail Sets New Standard in Global Physical Records Management and File Tracking 3Health News:1st Plumbing Services Selected to be Exclusive Dealer in Austin, Texas for Installation of Easy Water No-Salt Water Conditioning System 2Health News:1st Plumbing Services Selected to be Exclusive Dealer in Austin, Texas for Installation of Easy Water No-Salt Water Conditioning System 3
    Foreign body spud very thin, lightly curved and rounded tip....
    ... premium high water content ... permeability. Standard one fit ... the following therapeutic conditions: ... bullous keratopathy, recurrent ulcers, ...
    Bandage lenses....
    Guthrie skin hook with 2 prongs....
    Medicine Products: